Sophie Dobiasch

Sophie Dobiasch

Auto-generated profile, based on publicly available information

Sophie Dobiasch

Department of Radiation Oncology, TUM School of Medicine and Health, TUM Klinikum Rechts der Isar, Technical University of Munich (TUM), Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, a partnership between DKFZ and University Hospital Klinikum rechts der Isar, Germany; Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, Neuherberg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
KKKerstin Kessel
Kerstin Kessel
MVMarco Me Vogel
Marco Me Vogel
AAAnna Alles
Anna Alles
SDSophie Dobiasch
Sophie Dobiasch
HFHanna Fischer
Hanna Fischer
SCStephanie Combs
Stephanie Combs
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

20 October 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JRJohannes Roesch
Johannes Roesch
MOMichael Oertel
Michael Oertel
SWSimone Wegen
Simone Wegen
MTMaike Trommer
Maike Trommer
JSJulia Schleifenbaum
Julia Schleifenbaum
MHMarkus Hecht
Markus Hecht

29 June 2022 in Physics in Medicine & Biology
Verified
Journal Article
Open access
MDManuela Anna Duda
Manuela Anna Duda
AGAndreas Grad
Andreas Grad
SKSeverin Kampfer
Severin Kampfer
SDSophie Dobiasch
Sophie Dobiasch
SCStephanie Combs
Stephanie Combs
JWJan Jakob Wilkens
Jan Jakob Wilkens
Objective. Dual energy computed tomography (DECT) has been shown to provide additional image information compared to conventional CT and has been used in clinical routine for several years. The objective of this work is to present a DECT implementation for a Small Animal Radiation Research Platform (SARRP) and to verify it with a quantitative analysis of a material phantom and a qualitative analysis with an ex-vivo mouse measurement. Approach. For dual energy imaging, two different spectra are required, but commercial small animal irradiators are usually not optimized for DECT. We present a method that enables dual energy imaging on a SARRP with sequential scanning and an Empirical Dual Energy Calibration (EDEC). EDEC does not require the exact knowledge of spectra and attenuation coefficients; instead, it is based on a calibration. Due to the SARRP geometry and reconstruction algorithm, the calibration is done using an artificial CT image based on measured values. The calibration yields coefficients to convert the measured images into material decomposed images. Main results. To analyze the method quantitatively, the electron density and the effective atomic number of a material phantom were calculated and compared with theoretical values. The electron density showed a maximum deviation from the theoretical values of less than 5% and the atomic number of slightly more than 6%. For use in mice, DECT is particularly useful in distinguishing iodine contrast agent from bone. A material decomposition of an ex-vivo mouse with iodine contrast agent was material decomposed to show that bone and iodine can be distinguished and iodine-corrected images can be calculated. Significance. DECT is capable of calculating electron density images and effective atomic number images, which are appropriate parameters for quantitative analysis. Furthermore, virtual monochromatic images can be obtained for a better differentiation of materials, especially bone and iodine contrast agent.

17 September 2025 in Translational Oncology
Verified
Journal Article
Open access
CKChristopher Kessler
Christopher Kessler
FCFrancheska Cadacio
Francheska Cadacio
CMCarlo Maurer
Carlo Maurer
ASArlett Schäfer
Arlett Schäfer
FOFelix Orben
Felix Orben
SDSophie Dobiasch
Sophie Dobiasch
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with neoadjuvant radio(chemo)therapy failing in approximately 70 % of cases due to high tumor heterogeneity, and intrinsic radioresistance. Patient-derived organoids (PDOs) closely recapitulate appearance, and functionality as the original tissue and have potential to explore novel therapies for personalized radiooncology. In this study, the radioresponse of PDAC PDO lines was determined after irradiation (RT). PDOs were immunohistochemically characterized by γ-H2AX, HIF-1α and Ki-67 staining. RNA sequencing data were analyzed by gene set enrichment analyses to investigate underlying mechanisms of radioresistance. Preclinical findings were correlated with clinical data from the corresponding patients. PDOs showed a significant heterogeneity in response to radiation and were classified into radiosensitive, intermediate, and radioresistant subgroups. A correlation between radiosensitivity and enhanced proliferation and decreased hypoxia was observed. OXPHOS-related gene signatures were significantly overexpressed in the radioresistant phenotype. Translationally, radioresistance in PDOs was associated with significantly poorer survival of patients. Our platform demonstrated heterogeneity in radioresponse reflecting the clinical situation and correlation with clinical outcomes. Immunohistochemical staining and transcriptomic profiling identified molecular signatures, including HIF-1α and OXPHOS-related pathways, associated with radioresistance. Implementing PDO-based radioresponse profiling in clinical workflows may enable patient stratified treatment approaches. Overall, our findings suggest that functionalizing PDOs for radioresponse might extend PDO-informed precision oncology.

24 November 2017
Verified
Preprint
Open access
KKKerstin Kessel
Kerstin Kessel
MVMarco M E Vogel
Marco M E Vogel
AAAnna Alles
Anna Alles
SDSophie Dobiasch
Sophie Dobiasch
HFHanna Fischer
Hanna Fischer
SCStephanie Combs
Stephanie Combs
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.